Alert: Falsified (Contaminated) USP/EP Propylene Glycol – Medical Product Alert N°1/2024
Alert Overview This alert from the World Health Organization (WHO) addresses the discovery of falsified DOW USP/EP Propylene Glycol in Pakistan. Authentic DOW USP/EP Propylene Glycol is a crucial raw material used in pharmaceutical and other manufacturing processes, meeting the…
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Viatris, a leading global healthcare company, has announced the appointment of Corinne Le Goff as its Chief Commercial Officer, effective immediately. Le Goff brings over 25 years of experience in the biotechnology and pharmaceutical sectors, having successfully led and nurtured…
WuXi Biologics Chosen for S&P Global Sustainability Yearbook 2024
WuXi Biologics, known as WuXi Bio (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces its selection for the prestigious S&P Global Sustainability Yearbook 2024 (“Yearbook”) in recognition of its outstanding sustainability performance throughout 2023. The…
Labcorp Unveils Groundbreaking Blood Test for Early Detection of Neurodegenerative Diseases and Brain Injuries
Labcorp, a leading provider of innovative laboratory services globally, has announced the launch of the nation’s inaugural glial fibrillary acidic protein (GFAP) test. This test serves as a pivotal blood-based biomarker aiding in the early detection of neurodegenerative diseases and…
FDA Approves TEVIMBRA® for Advanced Esophageal Cancer Post-Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) has received FDA approval for TEVIMBRA® (tislelizumab-jsgr) as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have undergone prior systemic chemotherapy not including a PD-(L)1…
Novartis’ Fabhalta® (iptacopan) reduces proteinuria by 38.3% in IgA Nephropathy Patients
Novartis recently shared promising findings from the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), a Factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy (IgAN). In this interim analysis, patients treated with Fabhalta experienced a significant…
Unveiling the Growing Impact of Chronic Kidney Disease on Patients, the Environment, and Economies
A recent modeling analysis conducted by AstraZeneca, named IMPACT CKD, projects that by 2032, up to 16.5% of the population across eight countries will be afflicted by chronic kidney disease (CKD), with an expected increase of up to 59.3% in…
Modalis Announces Partnership with Ginkgo Bioworks
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo’s global customers in the cell and gene therapy fields…
Agenus Reveals Latest Phase 1 Findings and Advances in BOT/BAL Development for Metastatic MSS Colorectal Cancer
Agenus Inc. (NASDAQ: AGEN), a renowned player in the realm of discovering and advancing novel immunological treatments for diverse cancers, has disclosed the latest outcomes from its Phase 1 clinical assessment of BOT/BAL combination therapy targeting patients with metastatic CRC…
Revance Unveils Latest DAXXIFY® Findings at the 2024 American Academy of Neurology Annual Conference
Revance Therapeutics, Inc. (NASDAQ: RVNC) has unveiled significant insights into DAXXIFY® for the treatment of cervical dystonia at the American Academy of Neurology (AAN) annual meeting, running from April 13-18, 2024, in Denver, Colorado. The presentations, ASPEN-1 and ASPEN-OLS (open…
Dermal Fillers Market 2023-2035: Hyaluronic Acid Innovation Drives Expansion – ResearchAndMarkets.com
Introducing the latest addition to ResearchAndMarkets.com’s offerings, the report on the “Global Dermal Fillers Market, 2023-2035”. Estimated at $3 billion in 2023, the global dermal fillers market is poised for robust growth, projected at a compound annual growth rate (CAGR)…
Comparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes
TheracosBio has recently published a study titled “Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: a 24-week, randomized, double-blind, active-controlled, phase 3 trial” in the Journal of…